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ARTICLE
Mutational and putative neoantigen load predict
clinical beneﬁt of adoptive T cell therapy in
melanoma
Martin Lauss1, Marco Donia2,3, Katja Harbst1, Rikke Andersen2,3, Shamik Mitra1, Frida Rosengren1,
Maryem Salim1, Johan Vallon-Christersson 1, Therese Törngren1, Anders Kvist 1, Markus Ringnér 4,
Inge Marie Svane2,3 & Göran Jönsson1
Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded
remarkable response rates and many durable responses in clinical trials in melanoma;
however, 50–60% of the patients have no clinical beneﬁt. Here, we searched for predictive
biomarkers to ACT in melanoma. Whole exome- and transcriptome sequencing and
neoantigen prediction were applied to pre-treatment samples from 27 patients recruited to a
clinical phase I/II trial of ACT in stage IV melanoma. All patients had previously progressed
on other immunotherapies. We report that clinical beneﬁt is associated with signiﬁcantly
higher predicted neoantigen load. High mutation and predicted neoantigen load are sig-
niﬁcantly associated with improved progression-free and overall survival. Further, clinical
beneﬁt is associated with the expression of immune activation signatures including a high
MHC-I antigen processing and presentation score. These results improve our understanding
of mechanisms behind clinical beneﬁt of ACT in melanoma.
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The clinical management of metastatic melanoma wasrevolutionized by the advent of immunotherapies. Cellularimmunotherapy, namely adoptive T-cell therapy (ACT)
using tumor inﬁltrating lymphocytes (TILs), has demonstrated
very high objective response rates, and long-lasting complete
tumor regression in up to 20–25% of treated patients in clinical
trials1–4. However, ACT is a complex, costly, and highly intensive
treatment which to date is reserved to patients with good per-
formance status. About 50% of melanoma patients do not appear
to have any beneﬁt from current ACT protocols. Therefore, the
development of reliable predictive criteria to identify these
patients is of high clinical importance. In addition, a deeper
understanding of mechanisms of primary resistance may guide
modiﬁcation of the classical protocols to improve the efﬁcacy of
ACT.
Intrinsic features of the TILs infused, such as the number of
tumor reactive T cells, their differentiation status as well as their
persistence in circulation, have been found to associate with
clinical beneﬁt from ACT2, 3, 5, 6. However, these analyses cannot
be used to select patients to be treated as they are performed after
the ACT treatment is completed.
Novel molecular analyses are providing important insights on
which genomic and immunological characteristics are associated
with tumor progression and response to therapy. High mutational
and putative neoantigen load have been found to correlate with
clinical beneﬁt from immune checkpoint blockade therapy in
lung cancer and melanoma7–11. Previous reports have identiﬁed
neoantigens as the target of T-cell responses both in patients
treated with ACT12–14 and immune checkpoint blockade15, 16.
Immune activation gene-expression signature deﬁnes a distinct
subtype in melanoma17, 18. Relative prevalence of pre-existing
CD8+/PD-1+/CTLA-4+ tumor inﬁltrating T cells appears to
correlate to response to anti-PD-119. Furthermore, high fre-
quency of circulating myeloid-derived suppressor cells (MSDCs)
correlates with poor response to anti-CTLA420, 21, whereas the
expression of cytolytic markers correlates with improved response
to anti-CTLA48.
These observations prompted us to investigate the impact of
tumor molecular alterations on response to ACT in melanoma
patients in a clinical phase I/II trial6, 22. We subjected the tumors,
which TILs were derived from, to whole-exome and RNA
sequencing. We show that clinical beneﬁt is associated with high
mutational and predicted neoantigen load and elevated immune
signature, including a high MHC class I antigen presentation
score, while absence of beneﬁt can be linked to downregulated
antigen processing and presentation machinery (APM).
Results
Patient cohort and tumor biopsies. To explore the underlying
biology of response to ACT in melanoma, we assembled a set of
27 patients enrolled in a clinical phase I/II trial of ACT (Clin-
icalTrials.gov Identiﬁer: NCT00937625)6, 22 and analyzed tumor
samples obtained for the expansion of TILs, prior to ACT
initiation. The majority of tumor biopsies were obtained from
lymph node or subcutaneous metastases. All patients had pre-
viously been treated with and failed other immunotherapy, the
majority receiving both IL-2 and anti-CTLA4 treatment. Notably,
two patients had a mucosal primary melanoma and four had an
unknown primary tumor. Two patients received BRAF inhibitors
prior to biopsy and ACT, and three patients were on BRAF
inhibitor treatment when biopsy was obtained for ACT.
According to RECIST criteria there were ﬁve complete respon-
ders (CR), seven partial responders (PR), ten with stable disease
(SD) and ﬁve with progressive disease (PD). All patients had a
minimum follow-up of 37.2 months. Patients with clinical beneﬁt
were deﬁned as CR, PR or otherwise with an OS time of more
than 2 years (Table 1). Detailed clinical characteristics of this
cohort were previously reported in other publications6, 22.
Mutational load is associated with outcome from ACT. The
mutational landscape of 27 pre-treatment melanoma tumors and
matched lymphocyte DNA was investigated by whole-exome
sequencing (WES). Three out of 27 pre-treatment samples failed
exome sequencing. We achieved a median coverage of 104×
(median tumor coverage 98×; median normal coverage 110×).
We detected a median of 286 somatic mutations in the 24 tumors
(range 23–2,200). Notably, the two mucosal melanomas had 157
and 246 somatic mutations, respectively. The association of
mutational burden and ACT responses is shown in Fig. 1. We
found a trend (P= 0.12, Kruskal–Wallis test) that clinical
responses deﬁned by RECIST criteria were associated with
mutational load. Patients with CR (median= 618) had the highest
mutational load and patients with PD (median= 110) had the
lowest mutational load while patients with PR (median= 433)
and SD (median= 214) displayed intermediate mutational
load (Fig. 2a). Next, we divided the cohort in patients with
clinical beneﬁt and no clinical beneﬁt, deﬁned as described in
Methods section. We found that patients with clinical beneﬁt
harbored more somatic mutations (median= 496) as compared
to those without clinical beneﬁt (median= 169), (P= 0.01,
Mann–Whitney test, Fig. 2b). In addition to examining muta-
tional load in relation to response as deﬁned by RECIST criteria
and tumor regression, we also investigated mutational load in
relation to patient survival. As expected, there was a signiﬁcant
difference in patient survival when comparing clinical beneﬁt and
no clinical beneﬁt (Supplementary Fig. 1, P= 2 × 10−7, Cox
regression). Patients were then stratiﬁed in three equally large
groups based on mutational burden. Indeed, patients with the
highest mutational burden (median 647, range 496–2200) had
superior survival and patients with the fewest (median 98, range
23–193) somatic mutations had the worst outcome, while patients
harboring intermediate (median 286, range 194–495) amount of
somatic mutations also had intermediate survival (Fig. 2c, d).
Patients belonging to the group with the highest mutational load
had a 1-year progression-free survival (PFS) rate of 63%, the
intermediate group 25%, and the low group had no patients with
more than one-year PFS (Fig. 2c). Hence, mutational load is a
strong predictive biomarker in ACT. Further conﬁrmation that
mutational load is a predictive biomarker for immune therapy
came from Hugo et al.11 demonstrating that survival after PD1-
inhibition treatment is associated with mutational load. Overall,
our ﬁndings suggest that mutational burden may be a good
predictive biomarker for immunomodulatory agents in
melanoma.
Mutational and copy number patterns and beneﬁt of ACT.
Several genes have been suggested to be driver genes in mela-
noma18. We addressed the role of mutations in these genes in
response to ACT (Fig. 3a). BRAF V600 mutation was found in
58% and NRAS Q61 mutation in 21% of all cases. Two cases had
NF1 missense mutations; however, these cases also carried a
BRAF V600 and an NRAS Q61 mutation, respectively. Five cases
lacked mutations in BRAF, NRAS, and NF1. Driver gene muta-
tions were fully clonal except for a TP53 mutation in one patient
(Fig. 3a). Gene mutation frequencies did not differ signiﬁcantly
between clinical beneﬁt and no clinical beneﬁt groups. Previously,
mutation in the BRCA2 gene was found to be associated with
intrinsic resistance to PD1 inhibition11. Herein, we found two
cases with clinical beneﬁt and one case without clinical beneﬁt
harboring BRCA2 missense mutation (Fig. 3a). Hence, BRCA2
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mutation cannot explain poor response to ACT in our cohort.
While UV-radiation induced DNA damage was the dominant
source of mutations, the presence of additional mutational sig-
natures was suggested in a few patients (Supplementary Fig. 2).
We next investigated DNA copy number changes in relation to
response to ACT. The fraction of genome altered was not
associated with clinical beneﬁt after therapy (Fig. 3b). Of the
genes with known ampliﬁcations and deletions in melanoma, the
CDKN2A locus showed a considerable deletion frequency
(Fig. 3a). However, the cases with CDKN2A loss had diverging
RECIST outcome. Notably, deletions of the interferon (IFN) locus
located next to the CDKN2A gene have been shown to associate
with resistance to anti-CTLA4 treatment23. In this cohort, ﬁve
tumors in the clinical beneﬁt group and three tumors in the no
clinical beneﬁt group harbored deletions of the IFN locus, hence
there was no statistical difference between the groups (P> 0.6,
Fisher's Exact test), Acquired loss-of-function alterations in the
B2M gene, whose protein product beta-2-microglobulin is an
essential part of the MHC-I complex, has been identiﬁed in
relapse lesions following treatment with PD1 inhibitor24. In our
cohort, the B2M gene was heterozygously deleted in six patients
and four of these patients had a PFS <1 year (Fig. 3a). Three of
the six patients with B2M deletion had a clinical beneﬁt from
ACT and two of these were objective responders according to
RECIST (Fig. 3a). Furthermore, no difference in B2M gene
expression was found between cases with or without B2M loss (P
= 0.30, t-test) suggesting that B2M is still functional in deleted
cases. Importantly, no case harbored B2M somatic mutation.
Moreover, no difference in DNA copy number gains at the HLA-
locus was identiﬁed and we only found one case of PD-L1 gene
ampliﬁcation (Fig. 3a). Collectively, speciﬁc mutations or DNA
copy number alterations are not predictive of response to ACT.
Immune activation in patients who beneﬁt from ACT. Previous
studies have deﬁned transcriptional melanoma subgroups
expressing high levels of immune response associated genes17, 18.
Increased messenger RNA levels of such genes are associated with
an improved outcome in primary and stage III metastatic mela-
noma25, 26. Thus, it is tempting to speculate that such tumors may
Table 1 Patient characteristics of the analyzed cohort
Patient
ID
Previous systemic
therapya
Type of
lesionb
Type of
primary
RECIST Clinical beneﬁt Treatment post ACTa WES
data
RNAseq
data
Pat1 IL-2 LN Unknown CR Clinical beneﬁt None Yes
Pat2 IL-2, DC LN Skin PD No clinical
beneﬁt
Tem Yes Yes
Pat3 IL-2, DC SC Unknown SD No clinical
beneﬁt
Tem Yes Yes
Pat4 IL-2 LN Skin PD No clinical
beneﬁt
None Yes Yes
Pat5 IL-2, Ipi, DC LN Skin CR Clinical beneﬁt None Yes Yes
Pat6 IL-2, Tem, Ipi, DC LN Unknown PD No clinical
beneﬁt
None Yes Yes
Pat7 IL-2 LN Skin CR Clinical beneﬁt None Yes Yes
Pat8 IL-2, Ipi SC Skin SD Clinical beneﬁt Pembro Yes Yes
Pat9 Ipi, IL-2 LN Skin PR Clinical beneﬁt None Yes Yes
Pat10 IL-2, Ipi, Tem SC Skin PR Clinical beneﬁt ACT, Ipi Yes
Pat11 IL-2, Ipi NA Skin PR Clinical beneﬁt None Yes Yes
Pat12 Ipi, IL-2, BRAFi LN Skin PR Clinical beneﬁt None Yes
Pat13 IL-2, Ipi LN Skin SD No clinical
beneﬁt
BRAFi Yes Yes
Pat14 Ipi IM Skin CR Clinical beneﬁt None Yes Yes
Pat15 Ipi, IL-2, BRAFi SC Skin PD No clinical
beneﬁt
None Yes Yes
Pat16 IL-2, DC, Ipi, BRAFi LN Skin SD No clinical
beneﬁt
Tem Yes
Pat17 IL-2, Ipi SC Mucosal PR Clinical beneﬁt Tem Yes Yes
Pat18 IL-2, Ipi, Tem LN Mucosal SD No clinical
beneﬁt
Nivo Yes Yes
Pat19 IL-2, Ipi, BRAFi SC Skin SD No clinical
beneﬁt
Pembro, BRAFi, BRAFi/MEKi, Tem Yes Yes
Pat20 IL-2, Ipi, BRAFi IA Skin PR Clinical beneﬁt ACT, Pembro, BRAFi, Tem, Sel,
KPT-330
Yes Yes
Pat21 IL-2, Ipi SC Skin SD No clinical
beneﬁt
BRAFi, Tem Yes Yes
Pat22 Ipi, IL-2 IA Skin SD No clinical
beneﬁt
BRAFi, Tem, Pembro, Yes Yes
Pat23 IL-2, Ipi SC Skin CR Clinical beneﬁt None Yes Yes
Pat24 IL-2, Tem SC Unknown PD No clinical
beneﬁt
Ipi, Pembro Yes Yes
Pat25 IL-2, Ipi, BRAFi LN Unknown PR Clinical beneﬁt Pembro Yes
Pat26 IL-2, Ipi LN Skin SD Clinical beneﬁt Pembro, BRAFi, BRAFi/MEKi, Tem Yes Yes
Pat27 IL-2, Ipi Pleura Unknown SD No clinical
beneﬁt
Pembro, Tem Yes Yes
aBRAFi BRAF inhibitor; DC Dacarbazine; Ipi Ipilimumab; MEKi MEK inhibitor; Nivo Nivolumab; Pembro Pembroluzimab; Sel Selinexor; Tem Temodal
bIA intra-abdominal; IM intra-muscular; LN lymph node; SC subcutaneous
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have an improved response to immunotherapy. Herein, we per-
formed RNA sequencing of 25 melanoma biopsies of the
27 samples obtained prior to ACT to determine transcriptional
features associated with response to ACT. First, we used the 1500
most variable genes and performed hierarchical clustering and
did not observe any clear correlation between response to ACT
and the cluster dendrogram (Supplementary Fig. 3). Next, we
classiﬁed all tumors using the IPRES signature previously shown
to be predictive of response to PD1-inhibition11. In total, we
found ﬁve IPRES-enriched cases in patients with no clinical
beneﬁt and ﬁve IPRES-enriched cases without clinical beneﬁt
(P= 1, Fisher's Exact test). OS rates were comparable for IPRES-
enriched and IPRES-not-enriched cases (P= 0.8, Cox regression,
Supplementary Fig. 4) thus suggesting that the IPRES signature is
not predictive of response to ACT.
We then compared the transcriptomes of tumors from patients
displaying clinical beneﬁt to those with no clinical beneﬁt. Gene
set enrichment analysis (GSEA) indicated the up-regulation of
immune system associated genes in patients with clinical beneﬁt,
and in addition indicated a role for IFN-gamma signaling (GSEA,
fdr= 0). This was supported by gene ontology analysis using
DAVID27 (Supplementary Table 1). Tumors from patients with
no clinical beneﬁt were found to have relatively high expression
levels of genes involved in the cell cycle (GSEA, fdr= 0, Fig. 4a).
Although, signiﬁcant pathways in the GSEA included chromo-
some maintenance (fdr= 0) and meiotic recombination (fdr= 0)
it was dominated by cell cycle and proliferation related signatures
(Supplementary Table 1). Further analysis showed that the core
genes of the MHC-I antigen presentation pathway were strongly
correlated across the cohort and that the expression of several
antigen presentation genes was relatively high in tumors from
patients with clinical beneﬁt. Thus, we constructed a gene-
expression score for the activity of MHC-I antigen presentation
(Fig. 4b, Supplementary Fig. 5) and observed that the samples
with the highest MHC-I score (top 25%) were all derived from
patients with excellent outcome albeit the PFS analysis was not
signiﬁcant (Fig. 4c). These results suggest that up-regulation of
immune system associated genes and MHC class I dependent
antigen presentation is associated with ACT efﬁciency in
melanoma. To further dissect these ﬁndings, we again turned to
the Hugo et al. dataset but intriguingly could not ﬁnd a strong
correlation of MHC-I antigen presentation genes (Supplementary
Fig. 6). Furthermore, we did not observe a difference in survival
based on MHC-I gene score activity in the anti-PD1 treated
cohort (Supplementary Fig. 6). Finally, we analyzed the
prognostic effect of the MHC-I gene score in the TCGA18 and
Cirenajwis et al.26 cohorts. In both cohorts the MHC-I genes were
tightly co-expressed and showed a prognostic effect in metastatic
melanoma (Supplementary Fig. 6).
Recently, Tirosh et al.28 performed single-cell RNA sequencing
of cancer and immune cells derived from metastatic melanoma
tumors and generated single immune cell signatures. In order to
elucidate the composition of the immune cell inﬁltrate and
potential role of individual immune cell types in response to ACT
in melanoma, we applied these signatures to our data. For further
comparison we applied these signatures to the TCGA data as well.
Here, we found T- and B-cell signatures associated to survival in
stage IV melanomas (Supplementary Fig. 7). However, when
applying the signatures to the ACT data we found no association
between any particular immune cell type and clinical beneﬁt
(Fig. 4d) and furthermore no association to survival was observed
(Supplementary Fig. 8). Similarly, we found no association of
single immune cell markers (Fig. 4d) or ratios thereof
(Supplementary Fig. 9) to clinical beneﬁt. These analyses indicate
that immune cell inﬁltration was favorable for ACT outcome,
rather than the presence of a speciﬁc immune cell type.
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Intriguingly, both T-cell exhaustion markers and IFN-signaling
genes showed a trend towards up-regulation in tumors from
patients with clinical beneﬁt, with the majority of the genes not
reaching signiﬁcance. Genes demonstrating some association to
clinical beneﬁt included CTLA4, HLA-C, and TAP2 (P< 0.05, t-
test) however there were several genes displaying borderline
association including JAK2, PDL1, HLA-B, HLA-DRB1, and B2M
(Fig. 4d). The role of these pathways that control T-cell activity
will have to be explored in a larger dataset. Melanoma cell lineage
signatures, deﬁned by MITF and AXL scores28, as well as cAMP-
signaling associated genes, previously linked to MAPKi resistance
in melanoma29, were equally expressed in tumors from patients
with and without clinical beneﬁt (Fig. 4d), suggesting that the
activity of melanoma cell intrinsic programs does not inﬂuence
clinical efﬁcacy of ACT. Finally, we wanted to explore the
relationship between tumor-immune gene-expression signatures
and mutational load. We used the T-, B-cell and macrophage
signatures by Tirosh et al28 however we did not ﬁnd any
correlation between expression signatures and mutational load
(Supplementary Fig. 10). Consequently, no correlation was found
between the MHC-I gene-expression score and mutational load
(Supplementary Fig. 10). Collectively, tumor-immune micro-
environmental processes rather than melanoma lineage tran-
scriptomic signatures are associated with ACT efﬁcacy in
melanoma. Such tumor-immune signatures are independent of
mutational load.
Predicted neoantigen load is associated with beneﬁt of ACT.
Melanoma is one of the most neoantigen rich cancer forms30. The
association of high predicted neoantigen load and favorable
outcome following immune checkpoint inhibition therapy has
been reported in NSCLC and melanoma8–10. We sought to
address the relationship between putative neoantigen load and
clinical beneﬁt from ACT in patients who previously progressed
on immune therapy. We identiﬁed a median of 96 predicted
neoantigens in the 23 tumors (range 6–709). Of these, 31 (37%)
were expressed (range 4–183) as assessed by variant allele read
counts from RNA sequencing data (Fig. 5a). Interestingly, BRAF
V600E mutation was predicted to form a neoantigen when pre-
sented by HLA-A0301 or HLA-A1101. Similarly, NRAS Q61K/L/R
mutations were predicted to generate neoantigens in the presence
of certain HLA-A alleles. We assessed whether putative neoan-
tigen load was associated with clinical beneﬁt in our study.
When dividing the cohort by RECIST-deﬁned response, median
predicted neoantigen count followed response, with patients
achieving CR having a median of 85 expressed predicted
neoantigens, PR–32, SD–20, and PD only 13 predicted neoanti-
gens (Fig. 5b). Furthermore, tumors obtained from patients with
clinical beneﬁt harbored a median of 58 expressed predicted
neoantigens, while those with no beneﬁt only had 18 (Fig. 5c).
Finally, we assessed whether tumor neoantigen load correlated
with patient outcome. Patients with the lowest predicted neoan-
tigen load (median 8, range 4–18) had worst survival as compared
to patients with the highest (median 85, range 57–183) predicted
neoantigen load and intermediate (median 31, range 19–56)
amount of predicted neoantigens (Fig. 5d). Importantly, predicted
expressed neoantigen burden correlated strongly with mutational
load (Pearson correlation 0.98). In conclusion, predicted
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neoantigen load is associated with clinical beneﬁt from ACT in
melanoma.
To test the independent effect of predicted neoantigen load and
the MHC-I score we used a multivariate Cox regression model.
Using log10-transformed predicted neoantigen count and MHC-I
gene-expression score values as variables, both were found to be
independent predictors of OS (P= 0.007 and P= 0.01, respec-
tively, Cox regression). Collectively, these results demonstrate
that predicted neoantigen load is associated with OS and is
independent of tumor-immune micro-environmental gene-
expression signatures.
Discussion
The high response rates with long-term complete tumor regres-
sions make ACT a highly promising therapeutic modality in
metastatic melanoma. Currently, ACT is being developed in
several other forms of solid tumors including sarcomas31, cervi-
cal-32, ovarian-33, renal-34 and gastrointestinal cancers35. In an
attempt to increase the efﬁcacy of ACT, various adjustments to
the classical treatment protocol and combinations with other
therapeutics are under investigation in multiple trials (source:
clinicaltrials.gov). However, although there is an unmet need for
patient stratiﬁcation prior to ACT, patients with melanoma are
currently not preselected for ACT clinical trials based on tumor
characteristics, since these have not been comprehensively stu-
died in relation to response to ACT.
Here, we report the results from a comprehensive genomic
analysis of tumor samples from a phase I/II clinical trial of ACT
in melanoma. Our data provide compelling evidence that a high
mutational and predicted neoantigen tumor load is associated
with improved clinical outcome following ACT. The same phe-
nomenon was previously reported to associate with the outcome
of patients with melanoma or lung cancer, following treatment
with immune checkpoints inhibitors7–10, highlighting the
importance of neoantigens in response to immunotherapy.
Since melanoma and lung cancer have the highest average
mutational load of all tumor types36, this phenomenon probably
reﬂects an increased likelihood of forming neoantigens that will
elicit T-cell reactivity, thereby explaining why unselected mela-
nomas also show the highest clinical response rates following
current checkpoint-immunotherapy37. Importantly, all patients
enrolled in the current study had failed on prior immu-
notherapies such as intravenous IL-2 and/or anti CTLA-4 anti-
bodies, and mutational load still was signiﬁcantly associated with
clinical beneﬁt from ACT. Although, these results are intriguing
larger studies are a necessity to reﬁne thresholds of mutational
load as well as further validation of mutational load as
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a predictive biomarker. In addition, in this study we analyzed the
same biopsies used to manufacture TILs for infusion. In order to
ﬁt into common clinical settings, it might be desirable to know in
advance the likelihood of a given individual patient to beneﬁt
from ACT. Thus further validation of these biomarkers
with genomic analyses performed on earlier tumor biopsies,
e.g., obtained before enrollment in ACT protocol, is needed.
Importantly, the potential use of such predictive biomarkers
would ﬁt into current clinical paradigms because, after the
introduction of checkpoint- and BRAF- inhibitors, ACT is no
longer considered as a ﬁrst line therapy in melanoma because of
toxicity and complexity. Therefore, performing such genomic
analyses early in the metastatic disease may leave ample time to
identify patients that potentially will beneﬁt from ACT as salvage
therapy.
Presentation of tumor-antigens through the MHC class I APM
pathway is required for tumor-recognition from cytotoxic CD8 +
T cells38. Previous case reports have shown acquired loss of MHC
class I antigen presentation, e.g., through loss of B2M in mela-
noma metastases, suggesting importance of T-cell mediated
immune response at advanced stages of disease39, 40. Here, a high
expression of MHC class I APM genes was associated to clinical
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beneﬁt. Four out of six patients with a heterozygous loss of the
B2M gene had a very poor PFS; however three patients with B2M
loss had a clinical beneﬁt of ACT. This indicates that there may
be B2M-independent mechanisms for T-cells to recognize the
tumor cells and that B2M loss alone is not a good predictive
marker for ACT response. Intriguingly, analyses of previously
published patient cohorts revealed that MHC class I APM
pathway genes were not co-expressed, and did not predict
response to PD1 inhibition in melanoma11. While all patients in
the present study had received and failed immunotherapies prior
to ACT, there is no record of previous immunotherapy in the
cohort from Hugo et al.11. This observation might reﬂect
immunological editing of tumors induced by prior immu-
notherapies in some patients. Taken together, these ﬁndings
suggest that functioning of the MHC class I APM above a certain
threshold level is a necessary condition to respond to immu-
notherapies based on T-cell attack. One important implication is
that loss of an efﬁcient MHC class I APM may prevent the
beneﬁcial effects of the same immunotherapies, but further stu-
dies should clarify whether this can be used as an entry criterion
for ACT protocols and/or other immunotherapies.
In this study, although general activation of the immune
response was signiﬁcantly associated with clinical beneﬁt from
ACT, we did not observe association of speciﬁc immune cell type
markers (e.g., T cell, B cell, macrophage, and regulatory T cell) or
various ratios thereof, including cytolytic activity41, to clinical
beneﬁt. Taking into account previous reports showing that T-cell
inﬁltration17 and T-cell expression signature42 are positive
prognostic factors in immunotherapy naïve patients, as we also
demonstrate in the TCGA cohort, this may reﬂect the effect of
prior immunotherapies on immune cell inﬁltration, as these
signatures were not predictive of survival in the current cohort of
patients treated with ACT. While loss of MITF is associated to
resistance to MAPK inhibition43, expression of MITF and AXL
was not associated to clinical beneﬁt from ACT in our data;
therefore, melanoma cell features such as lineage and
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differentiation may play a minor role in deﬁning response to
immunotherapy. Finally, up-regulation of cell cycle genes appears
to be an adverse predictive factor of ACT in melanoma, in line
with previous ﬁndings of poor prognosis associated with pro-
liferation in melanoma17, 25, 26. Intriguingly, our results further
demonstrated that predicted neoantigen load and tumor-immune
gene-expression signatures are independent predictors of survival
in this ACT treated cohort. This suggests that a composite bio-
marker of neoantigen load and immune signatures should be
explored for prediction of response to immunotherapy in
melanoma.
In conclusion, our ﬁndings reveal tumor molecular features
associated with response to ACT that warrant further investiga-
tion. If conﬁrmed by independent studies, they can be used to
guide the application of ACT in melanoma and, potentially, other
solid tumors where ACT is currently under development.
Methods
Patient cohort and material. All patients of this study were enrolled in the clinical
trial NCT009376256, 22, where the efﬁcacy of ACT followed by attenuated doses of
interleukin-2 was investigated. All patients signed a written consent form. All
patients had stage IV melanoma and had received prior systemic therapy. Response
was assessed according to RECIST 1.0. In the cohort of 27 patients enrolled in the
trial the median overall survival (OS) was 22.8 months. Further, for the purpose of
statistical analyses, the cohort was divided into clinical beneﬁt and no clinical
beneﬁt; all patients with tumor response according to RECIST (PR or CR) or OS of
at least 2 years were deﬁned as patients with clinical beneﬁt. Two years was selected
as cutoff because of the median OS of 22.8 months. Only two patients in the clinical
beneﬁt group had an OS of less than 2 years, however both patients had an
objective tumor response according to RECIST. Clinical data are summarized in
Table 1. Altogether, pre-treatment tumor samples from 27 patients could be
analyzed. Following data were missing from pre-treatment samples: gene-
expression data: patients 10 and 12; copy number and mutation data: patients 1, 16,
and 25. For survival analysis, the database was locked on June 27th 2017 (Sup-
plementary Data 1).
Nucleic acid extraction and sequencing. Tumor DNA and RNA were extracted
using AllPrep DNA/RNA Mini Kit (Qiagen) from snap frozen or frozen in DMSO
tumor fragments. Normal DNA was derived from PBMCs or TILs using QIAamp
DNA Mini Kit (Qiagen). Tumor and normal DNA was subjected to WES library
preparation using SureSelect Target Enrichment System for Illumina Paired-End
Sequencing Library Protocol (Agilent Technologies) with Clinical Research Exome
(CRE) capture oligo panel (Agilent Technologies). Barcoded WES libraries were
pooled and sequenced on HiSeq 2500 (Illumina) in paired-end mode. RNA
sequencing was performed as previously described44.
WES data analysis. WES analysis including alignment, post-alignment processing,
and variant calling from WES data was performed as described previously44.
Brieﬂy, reads were mapped to the human reference genome (hg19) with decoy
using Novoalign (Novocraft Technologies), and duplicate fragments were marked
using the MarkDuplicates functionality of Picard tools. Local realignment and base
quality score recalibration were done using GATK. For variant calling, MuTect45
version 1.1.4 (default settings) and VarScan46 version 2.2.8 were used; for VarScan
somatic, minimum variant allele frequency in the tumor was set to 10%; following
recommendations from VarScan developers, somatic single-nucleotide variants
(SNV) calls were further ﬁltered to remove potential false positives; ﬁnally only
high conﬁdence calls were retained. For SNV, consensus of the two callers was
retained, while indels were derived using VarScan only. For variant annotation and
translation into protein sequence, Annovar47 was used; only mutations within the
coding sequence (CDS) regions of the genes were retained. Mutation data can be
found as Supplementary Data 3. Statistical analyses of total mutational load are
based on all mutations found in a particular sample. DNA copy number data were
generated using Contra48 version 2.0.3, and data were segmented using GLAD49.
DNA copy number data derived from WES data can be found as Supplementary
Data 2. Subclonality of mutations in the form of ‘cancer cell fraction’ was obtained
using ABSOLUTE50 version 1.0.6, with the setting copy_num_type= total and
without a minimum mutation allele frequency; the top model was selected.
Mutational signatures were derived using the R package deconstructSigs51 with the
reference signatures signatures.cosmic36.
HLA typing and neoantigen prediction. For HLA typing, sequencing libraries
were prepared from normal DNA using Illumina TruSight HLA Sequencing Panel
according to manufacturer’s instructions (Illumina) and sequenced on a MiSeq
instrument (Illumina). In addition, HLA type was derived from WES data of
normal (non-tumor) samples using bwakit (https://github.com/lh3/bwa/tree/
master/bwakit) or Omixon Target HLA (Omixon). Potential HLA class I restricted
neoantigens were predicted using a custom pipeline comprising modiﬁed pVAC-
Seq52. This early perl based version of pVAC-Seq was not able to generate pre-
dictions for indels. NetMHC version 4.0 was used for peptide-MHC afﬁnity pre-
dictions; mutated peptides with binding afﬁnity below 500 nM were retained;
pVAC-Seq sequencing depth based ﬁlter was not applied. Neoantigens supported
by minimum 2 variant RNA reads were considered expressed. In this study, we
have only used MHC class I predictions.
Expression signatures. RNAseq data were processed as previously described53
using TopHat254 and Cufﬂinks55 v2.1.1. Isoform FPKMs were summed up to
obtain gene-level expression. Data were quantile-normalized and log-transformed
by log2(data + 1). Genes were median-centered and reduced to protein-coding
genes deﬁned by the HGNC. SAM analysis56 was used to rank genes based on
differential expression scores, DAVID27 was used for GO-term analysis, and GSEA
with C2, C6, and C7 gene lists was used for GSEA57. Single-cell signatures and
melanoma lineage signatures were from Tirosh et al.28. The MHC-I APM displayed
high correlation of gene expression. In particular, HLA-A, HLA-B, HLA-C, TAP1,
TAP2, NLRC5, PSMB9, PSMB8, and B2M were highly correlated, and further
termed the “core” MHC-I set (Supplementary Fig. 5). The mean expression of these
core genes is the MHC-I score and was then divided in quartiles across patients to
test the association with OS. For the MHC-I score quartiles, the resulting bins were:
4th quartile [−2.98,−0.493], 3rd quartile (−0.493,0.196], 2nd quartile (0.196,0.728],
and 1st quartile (0.728,2.16]. The MHC-I score was subsequently applied to the
TCGA18 and Cirenajwis et al. cohorts26. To stratify the patients we again used the
MHC-I score quartiles determined in the respective data sets. We applied the
IPRES signatures to our cohort as speciﬁed in Hugo et al.11. Brieﬂy, 21 of 22
validated IPRES signatures were available, whereof 15 gene sets were available from
Broad MSigDB (http://software.broadinstitute.org/gsea/msigdb/) and six gene sets
were available from Supplementary Data from Hugo et al.11. The gene set variation
analysis (GSVA) scores were calculated from uncentered gene-expression data;
GSVA scores were transformed to z-scores and the mean z-score of the signatures
was obtained58. A cutoff of >0.35 was applied as described in Hugo et al.11 for a
sample to be called “IPRES-enriched”.
Data availability. RNAseq data have been deposited at Gene Expression Omnibus
with accession number GSE100797. Clinical annotation data, DNA copy number
data, and somatically called mutations are available as Supplementary Data 1–3,
respectively. All other remaining data are available within the article and Supple-
mentary Information Files, or available from the authors upon request.
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